A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena
- PMID: 2446463
- DOI: 10.1111/j.1600-0404.1987.tb03566.x
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena
Abstract
Eleven patients with severe Parkinson's disease and on-off-phenomena were included in a controlled double-blind study on the effect of electroconvulsive therapy (ECT). Pharmacological treatment was optimally adjusted before the trial. The severity of extrapyramidal symptoms was measured before, during and after the treatment. The patients were randomly allocated into one group, receiving active ECT and another, receiving sham treatment. The patients given active ECT showed significantly (P less than 0.05) prolonged duration of "on"-phases after ECT, in comparison to the sham-treated group. When collecting data from the controlled part of the study and the subsequent with open administration of ECT, the treatment was in addition found to significantly decrease the time and number of steps required to walk 10 meters. Moreover it reduced the severity of parkinsonian symptoms according to the Webster scale. The improvement induced by ECT was generally short-lasting. Lumbar punctures were performed before and after ECT. The concentrations of monoamine metabolites in cerebrospinal fluid were not affected by the treatment. The results indicate that ECT has an antiparkinsonian effect which probably is mediated via changed responsiveness of dopamine receptors and that further improvement is possible in patients, therapy resistant to the presently available medication.
Similar articles
-
ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides.J Neural Transm Park Dis Dement Sect. 1995;10(2-3):129-40. doi: 10.1007/BF02251228. J Neural Transm Park Dis Dement Sect. 1995. PMID: 9620060
-
Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment.Psychopharmacology (Berl). 1979 Aug 8;64(2):131-4. doi: 10.1007/BF00496052. Psychopharmacology (Berl). 1979. PMID: 115032
-
Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1704-8. doi: 10.1016/j.pnpbp.2011.05.003. Epub 2011 May 12. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21605615 Clinical Trial.
-
Treatment of Parkinson's disease with electroconvulsive therapy.Psychiatr Clin North Am. 1991 Dec;14(4):925-33. Psychiatr Clin North Am. 1991. PMID: 1771154 Review.
-
Electroconvulsive therapy (ECT) in Parkinson's disease: ECS and dopamine enhancement.J ECT. 2014 Jun;30(2):122-4. doi: 10.1097/YCT.0000000000000142. J ECT. 2014. PMID: 24810775 Review.
Cited by
-
Cell implantation in Parkinson's disease.BMJ. 1990 Sep 15;301(6751):556. doi: 10.1136/bmj.301.6751.556. BMJ. 1990. PMID: 2207434 Free PMC article. No abstract available.
-
The Use of ECT in the Elderly-Looking Beyond Depression.Curr Psychiatry Rep. 2022 Sep;24(9):451-461. doi: 10.1007/s11920-022-01353-0. Epub 2022 Jul 13. Curr Psychiatry Rep. 2022. PMID: 35829850 Review.
-
Acceptability of electroconvulsive therapy to patients with Parkinson's disease.J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):383-4. doi: 10.1136/jnnp.57.3.383-a. J Neurol Neurosurg Psychiatry. 1994. PMID: 8158197 Free PMC article. No abstract available.
-
In vivo neurochemical effects of electroconvulsive shock studied by microdialysis in the rat striatum.Psychopharmacology (Berl). 1991;103(3):343-50. doi: 10.1007/BF02244288. Psychopharmacology (Berl). 1991. PMID: 1711702
-
ECT in a patient with Parkinson's disease and schizophrenia, with dopamine transporter visualisation using 123I-ioflupane SPET.J Neural Transm (Vienna). 2011 Apr;118(4):647-50. doi: 10.1007/s00702-011-0615-8. Epub 2011 Feb 27. J Neural Transm (Vienna). 2011. PMID: 21359970
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical